Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...

BTIG Research assumed coverage on shares of NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) in a research report released on Wednesday morning, MarketBeat reports. The brokerage issued a buy rating ...

As of April 2, 2025, the average one-year price target for NRx Pharmaceuticals is $32.30/share. The forecasts range from a low of $19.19 to a high of $47.25. The average price target represents an ...

Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago focused on the development and commercialization of generic injectables, fertility, biologic, ...

Cadwell Industries, Inc., a global leader in neurodiagnostic, neuromonitoring and sleep solutions, launched its latest Sierratm software release providing patent-pending, fully-synchronized ...

RVPH Reviva Pharmaceuticals Holdings, Inc.

At close: 4 April at 4:00:00 pm GMT-4 ...